Journal of Epidemiology and Global Health

In Press, Corrected Proof, Available Online: 8 January 2020

Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay

Authors
Sunil Sethi1, *, #, Priyanka Agarwal2, #, Rajiv Khaneja3, Naresh Kumar4, Nitin Kumar5, Jagesh Chandna5, Ashutosh Nath Aggarwal6, Rakesh Yadav1
1Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2WHO Country Office for India, New Delhi, India
3State TB Cell, Sector 34, Chandigarh, India
4Directorate of Health Services, Sector 34, Chandigarh, India
5Intermediate Reference Lab, Patiala, Punjab, India
6Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India
#

First two authors are joint first author.

*Corresponding author. Email: sunilsethi10@hotmail.com
Corresponding Author
Sunil Sethi
Received 22 April 2019, Accepted 3 December 2019, Available Online 8 January 2020.
DOI
https://doi.org/10.2991/jegh.k.191215.003How to use a DOI?
Keywords
Drug resistance, diagnosis, MTBDRsl Ver 2.0, Mycobacterium tuberculosis
Abstract

Tuberculosis (TB) remains a main hurdle for national programs due to increase in drug resistance to antitubercular drugs. World Health Organization (WHO)-endorsed Line Probe Assay, Genotype MTBDRsl Ver 2.0, gives opportunity for rapid diagnosis and molecular characterization of different mutations in drug targets of fluoroquinolone (FQ) and second-line injectable drugs (SLID). We, retrospectively, analyzed the data of Genotype MTBDRsl Ver 2.0 from January 2018 to June 2018. A total of 863 isolates of Mycobacterium tuberculosis, 687 rifampicin resistant and 176 isoniazid resistant only, were screened for drug resistance in FQ and SLID. All the isolates were tested for Genotype MTBDRsl Ver 2.0 according to the manufacturer’s instructions. The FQ and SLID resistance were detected in 295 (34.2%) and 70 (8.1%) isolates, respectively. Among newly diagnosed and follow-up rifampicin-resistant TB (RR TB) patients, the FQ resistance was 25.8% and 44.5%, respectively. The most common mutation (42.7%) in FQ-resistant isolates was MUT3C in gyrA gene. Both SLID and FQ resistance were detected in 59 (6.8%) RR TB isolates. The mono SLID resistance was detected in 12 (1.7%) isolates of RR TB. Genotype MTBDRsl Ver 2.0 assay is a rapid and important tool for the diagnosis and molecular characterization of second-line drug resistance under programmatic conditions.

Copyright
© 2019 Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

Journal
Journal of Epidemiology and Global Health
Publication Date
2020/01
ISSN (Online)
2210-6014
ISSN (Print)
2210-6006
DOI
https://doi.org/10.2991/jegh.k.191215.003How to use a DOI?
Copyright
© 2019 Atlantis Press International B.V.
Open Access
This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Cite this article

TY  - JOUR
AU  - Sunil Sethi
AU  - Priyanka Agarwal
AU  - Rajiv Khaneja
AU  - Naresh Kumar
AU  - Nitin Kumar
AU  - Jagesh Chandna
AU  - Ashutosh Nath Aggarwal
AU  - Rakesh Yadav
PY  - 2020
DA  - 2020/01
TI  - Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay
JO  - Journal of Epidemiology and Global Health
SN  - 2210-6014
UR  - https://doi.org/10.2991/jegh.k.191215.003
DO  - https://doi.org/10.2991/jegh.k.191215.003
ID  - Sethi2020
ER  -